A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Advertisements

Volume 79, Issue 1, Pages (January 2013)

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

ALK FISH and IHC: You Cannot Have One without the Other

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Ground glass opacities: Imaging, pathology, and gene mutations

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer Anna Belilovski Rozenblum, MD, Maya.

P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations Ee Ke, Zhihong.

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies Zhong-Yi Dong, PhD, Chao Zhang, MD,

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma Jin Sung Jang, Xiaoke Wang,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors Hsin-Yi Wang, MD Journal of Thoracic.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

P Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas Hao-Ran Zhai, Jia-Tao Zhang,

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based.

Reliability Assurance of Detection of EML4-ALK Rearrangement in Non–Small Cell Lung Cancer: The Results of Proficiency Testing in China Yulong Li, MD,

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally.

MA17.05 Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas Hao-Ran Zhai, Shiyong Li, Bing Liao,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung.

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer Yan.

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

P Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI Y. Zhang, Q. Zhou,

Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma Filippo Lococo, MD,

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018 Jordi Remon, MD, Myung-Ju Ahn, MD, Nicolas Girard, MD, PhD, Melissa Johnson,

Presentation transcript:

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R E-E Ke, PhD, Qing Zhou, PhD, Qiu-Yi Zhang, MD, Jian Su, MMed, Zhi-Hong Chen, MMed, Xu-Chao Zhang, PhD, Chong-Rui Xu, PhD, Jin-Ji Yang, PhD, Hai-Yan Tu, MD, Hong-Hong Yan, MMed, Yi-Chen Zhang, MD, Fei-Yu Niu, PhD, Yi-Long Wu, MD Journal of Thoracic Oncology Volume 12, Issue 9, Pages 1368-1375 (September 2017) DOI: 10.1016/j.jtho.2017.05.018 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Percentages of each of the resistance mechanisms detected in the exon 19 deletion (Del19) (A) and L858R (B) subgroups. SCC, squamous cell carcinoma; MET, mesenchymal-epithelial transition proto-oncogene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; ALK, anaplastic lymphoma receptor tyrosine kinase gene. Journal of Thoracic Oncology 2017 12, 1368-1375DOI: (10.1016/j.jtho.2017.05.018) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Pooled analysis of seven studies on the prevalence of the T790M mutation (exon 19 deletion [Del19] versus L858R).11–16 Journal of Thoracic Oncology 2017 12, 1368-1375DOI: (10.1016/j.jtho.2017.05.018) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Overall survival (OS) of patients with different resistance mechanisms. MET, mesenchymal-epithelial transition proto-oncogene; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; ALK, anaplastic lymphoma receptor tyrosine kinase gene. Journal of Thoracic Oncology 2017 12, 1368-1375DOI: (10.1016/j.jtho.2017.05.018) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions